Clinical trials: Metastatic Malignant Neoplasm to Brain
Non-small Cell Lung Cancer (NSCLC), Brain Metastases
Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study
This multicenter study evaluates the efficacy and safety of furmonertinib 160mg versus furmonertinib 80mg plus chemotherapy (carboplatin + pemetrexed) as first-line treatment for EGFR-mutated NSCLC patients with brain metastases.
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Brain Metastases, Furmonertinib, EGFR Mutation
- Trial name
- NCT07365410
- Testing
- Furmonertinib, carboplatin, pemetrexed
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Metastatic Cancer
Radiation Therapy With or Without Surgery in Treating Patients Who Have Brain Metastases
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells in a single high dose. Combining radiation therapy with surgery may be a more effective treatment for brain metastases.
- Trial name
- NCT00003324
- Testing
- conventional surgery, radiation therapy
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Brain Metastasis From Advanced HER2-negative Breast Cancer
Evaluating the Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With VEX Metronomic Chemotherapy and Concurrent or Delayed Radiotherapy in Patients With Advanced HER2-Negative Breast Cancer With Brain Metastasis
A Prospective, multicenter, randomized controlled phase II study to evaluate the efficacy and safety of PD-L1 monoclonal antibody combined with vinorelbine + cyclophosphamide + capecitabine (VEX) metronomic chemotherapy and…
- Trial name
- NCT06839560
- Testing
- Adebrelimab+VEX Metronomic Chemotherapy+Concurrent Radiotherapy, Adebrelimab+VEX Metronomic Chemotherapy+Delayed Radiotherapy
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Breast Cancer, CNS Disease
ZK219477 (Sagopilone) in Patients With Breast Cancer and Brain Metastases
The purpose of this research study is to determine the effects (good and bad) of ZK219477(sagopilone) on participants and their cancer.
- Trial name
- NCT00496379
- Testing
- ZK219477
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Nancy Lin, MD
Brain Metastases
Memory Avoidance Whole Brain Radiotherapy vs Hippocampal Avoidance Whole Brain Radiotherapy (Athena 2 Trial)
Participants in this research study have cancer that has spread to their brain, called brain metastases. One treatment for this type of cancer is called whole brain radiotherapy that stays away from a specific neurocognitive…
- Trial name
- NCT07248228
- Testing
- MA-WBRT (Memory Avoidance Whole Brain Radiation Therapy (MA-WBRT)), HA-WBRT (Hippocampal Avoidance Whole Brain Radiation Therapy (HA-WBRT)), Memantine
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Case Comprehensive Cancer Center
Metastatic Cancer
Radiation Therapy With or Without RSR13 in Treating Patients With Brain Metastases
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as RSR13 may make tumor cells more sensitive to radiation therapy.
- Trial name
- NCT00005887
- Testing
- efaproxiral, radiation therapy
- Where
- 73 sites in United States, Australia and 7 more
- Sponsor
- Spectrum Pharmaceuticals, Inc
Metastatic Rectal Adenocarcinoma, Brain Metastases
BRIANSTORM - Early Identification of Patients With Brain Metastases
A single arm observational study investigating the incidence of brain metastasis in patients with cancer recti and lung metastasis
- Trial name
- NCT05185557
- Where
- Denmark
- Volunteers
- 50 people
- Sponsor
- Aarhus University Hospital
Phase II Clinical Trial, Ninety-six Histologically Confirmed NSCLC Patients With BM
Nitroglycerin Plus Intracranial Radiotherapy for Brain Metastases in NSCLC Patients
Background: Whole-brain radiotherapy (WBRT) is the standard treatment for multiple brain metastases (BM), in NSCLC patients who are not candidates for treatment with stereotactic radiation body therapy.
- Conditions
- Phase II Clinical Trial, Ninety-six Histologically Confirmed NSCLC Patients With BM, Randomized 1:1 to Received TN Plus WBR or Only WBR, ICPFS Evaluated by Two Blinded and Independent Radio-oncologist With MRI
- Trial name
- NCT04338867
- Testing
- Whole-brain radiotherapy
- Where
- Mexico
- Volunteers
- 96 people
- Sponsor
- Instituto Nacional de Cancerologia de Mexico
Brain Metastasases
Precision Radiotherapy for Refractory Brain Metastases: A Multicenter Study
Conventional image-guided techniques (such as cone-beam CT) have poor soft tissue contrast and unsatisfactory treatment outcomes.
- Trial name
- NCT07586657
- Testing
- adaptive radiotherapy
- Volunteers
- 200 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Melanoma, Brain Metastases
GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain Metastases
Ipilimumab adds a clinical benefit to radiation therapy in patients with melanoma metastatic to the brain. Melanoma is the third most common cancer causing brain metastases, after cancers of the lung and breast, which appears to…
- Trial name
- GRAY-B (NCT02115139)
- Testing
- Ipilimumab
- Where
- 12 sites in Spain
- Volunteers
- 58 people
- Sponsor
- Grupo Español Multidisciplinar de Melanoma
Breast Cancer, Brain Metastasis
T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery
Background: Sometimes breast cancer spreads (metastasizes) to the brain. Researchers want to study new treatments for brain metastases. The drug Temozolomide is approved to treat brain tumors.
- Conditions
- Breast Cancer, Brain Metastasis, Brain Cancer
- Trial name
- NCT03190967
- Testing
- T-DM1, TMZ
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Brain Tumor, Primary, Brain Tumor - Metastatic
Characterization of Circulating and Tumor-infiltrating Immune Cells in Malignant Brain Tumors
The goal of this observational study is to characterize the circulating leukocyte profile and the immune T cells distribution within the tumor in patients with malignant brain tumors and to correlate these findings with the…
- Trial name
- NCT05831631
- Testing
- Circulating leukocytes immunophenotype, Tumor sampling
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- Pietro Mortini, MD, Prof.
Astrocytoma, Glioblastoma
Detecting Malignant Brain Tumor Cells in the Bloodstream During Surgery to Remove the Tumor
Glioblastomas, the most frequent malignant brain tumor in adults, are widespread in the brain, despite their discrete appearance on computed tomography (CT) or magnetic resonance imaging (MRI).
- Conditions
- Astrocytoma, Glioblastoma, Glioma
- Trial name
- NCT00001148
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Brain Metastases
Evaluating AGuIX® Nanoparticles in Combination With Stereotactic Radiation for Brain Metastases
This study evaluates the clinical impact of AGuIX® nanoparticles in combination with Fractionated Stereotactic Radiation in oligo brain metastases.
- Trial name
- NANOSTEREO (NCT04094077)
- Testing
- AGuIX
- Where
- 2 sites in France
- Volunteers
- 1 people
- Sponsor
- Centre Leon Berard
Brain Cancer
A Phase II Study of Dacomitinib in Progressive Brain Metastases
The purpose of this study is to determine the disease response, survival, and side effects of an experimental drug called dacomitinib in progressive brain metastases.
- Trial name
- NCT02047747
- Testing
- Dacomitinib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- David Piccioni, M.D., Ph.D
Brain Metastases, Adult
A Window of Opportunity Study of Patritumab Deruxtecan in Patients With Brain Metastases
The purpose of this study is to determine if the study drug, patritumab deruxtecan (HER3-DXd), can be measured in brain tumor tissue after recieving one dose of patritumab deruxtecan before surgery.
- Trial name
- PARAMETer (NCT05620914)
- Testing
- Patritumab deruxtecan
- Where
- United States
- Sponsor
- Mustafa Khasraw, MBChB, MD, FRCP, FRACP
Melanoma
[18F]Dabrafenib Molecular Imaging in Melanoma Brain Metastasis
In this feasibility study, [18F]dabrafenib will be used as radioactive tracer. All patients in this study are diagnosed with advanced melanoma with evidence of brain metastases and are eligible for treatment with dabrafenib, a…
- Trial name
- NCT02700763
- Testing
- [18F]dabrafenib molecular imaging
- Where
- Netherlands
- Volunteers
- 1 people
- Sponsor
- University Medical Center Groningen
Cognitive/Functional Effects, Metastatic Cancer
Memantine in Preventing Side Effects in Patients Undergoing Whole-Brain Radiation Therapy for Brain Metastases From Solid Tumors
RATIONALE: Memantine may be able to decrease side effects caused by whole-brain radiation therapy. It is not yet known if memantine is effective in preventing side effects caused by whole-brain radiation therapy.
- Conditions
- Cognitive/Functional Effects, Metastatic Cancer, Neurotoxicity, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00566852
- Testing
- Memantine, Whole brain radiation therapy
- Where
- 235 sites in United States, Canada
- Volunteers
- 554 people
- Sponsor
- Radiation Therapy Oncology Group
Melanoma
PD-L1 PET Imaging in Melanoma Patients
This is a feasibility study for the use of [18F]PD-L1 as a PET tracer that will be conducted in a single center. The study consists of two phases.
- Trial name
- NCT03520634
- Testing
- PD-L1 PET imaging
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- University Medical Center Groningen
Lung Cancer, NSCLC
Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements
This study will consist of a Phase 1b and Phase 2 portion. The Phase 1b portion will enroll first followed by the Phase 2 portion. Each cycle of treatment = 28 days. Subjects will receive alectinib twice daily.
- Conditions
- Lung Cancer, NSCLC, Brain Metastases
- Trial name
- DURABLE (NCT05987644)
- Testing
- Alectinib, Stereotactic Radiosurgery
- Where
- 3 sites in United States
- Volunteers
- 56 people
- Sponsor
- Joshua Palmer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.